Nektar Therapeutics

NASDAQ:NKTR 1:00:00 PM EDT

24.76

-0.77 (-3.02%)

4:58:13 PM EDT: $24.57 -0.19 (-0.77%)

Market Cap (Intraday)	297.92M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$9.49 Million
Adjusted EPS	-$2.96

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Nektar Therapeutics Stock, NASDAQ:NKTR

455 Mission Bay Boulevard South, San Francisco, California 94158

United States of America

Phone: +1.415.482.5300

Number of Employees: 61

http://www.nektar.com

Description

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.